{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:40:38Z","timestamp":1768826438559,"version":"3.49.0"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T00:00:00Z","timestamp":1110240000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We investigated whether the incretin hormones glucagon\u2010like peptide\u20101 (GLP\u20101) and glucose\u2010dependent insulinotropic polypeptide (GIP), which are major regulators of glucose tolerance through the stimulation of insulin secretion, contribute to impaired glucose tolerance (IGT) among HIV\u2010infected patients on highly active antiretroviral therapy (HAART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eighteen HIV\u2010infected male patients (six lipodystrophic and 12 nonlipodystrophic) with normal glucose tolerance (NGT) were compared with 10 HIV\u2010infected male patients (eight lipodystrophic and two nonlipodystrophic) with IGT. Plasma concentrations of GLP\u20101 and GIP were determined frequently during a 3\u2010h, 75\u2010g glucose tolerance test. Insulin secretion rates (ISRs) were calculated by deconvolution of C\u2010peptide concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The incremental area under the curve (incrAUC) for GLP\u20101 was increased by 250% in IGT patients compared with NGT patients (1455\u00b1422 vs. 409\u00b1254 pmol\/L\/180\u2003min, respectively; <jats:italic>P<\/jats:italic>&lt;0.05), whereas the incrAUC for GIP did not differ between the study groups (7689\u00b11097 vs. 8041\u00b1998 pmol\/L\/180\u2003min, respectively; not significant). In pooled study groups, the GIP incrAUC correlated positively with the ISR incrAUC without adjustment (<jats:italic>r<\/jats:italic>=0.38, <jats:italic>P<\/jats:italic>&lt;0.05) and following adjustment for glucose incrAUC (<jats:italic>r<\/jats:italic>=0.49, <jats:italic>P<\/jats:italic>&lt;0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data suggest: (1) that glucose\u2010intolerant, HIV\u2010infected male patients may display enhanced GLP\u20101 responses to oral glucose compared with normal glucose\u2010tolerant HIV\u2010infected male patients, which may represent a compensatory mechanism rather than explain the IGT; (2) that the GIP response may be associated with ISR independently of plasma glucose in nondiabetic HIV\u2010infected males on HAART.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2005.00270.x","type":"journal-article","created":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T22:28:13Z","timestamp":1110320893000},"page":"91-98","source":"Crossref","is-referenced-by-count":7,"title":["Enhanced glucagon\u2010like peptide\u20101 (GLP\u20101) response to oral glucose in glucose\u2010intolerant HIV\u2010infected patients on antiretroviral therapy"],"prefix":"10.1111","volume":"6","author":[{"given":"O","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SB","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JJ","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CF","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"UB","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JO","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,8]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-16-3-390"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmr.5610080206"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.4.912"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7750"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.9.1640"},{"key":"e_1_2_10_7_2","first-page":"86","article-title":"Glucagon\u2010like peptide 1 has a physiological role in the control of postprandial glucose in humans","volume":"48","author":"Edwards CM","year":"1999","journal-title":"studies with the antagonist exendin 9\u201339"},{"key":"e_1_2_10_8_2","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal","volume":"81","author":"Willms B","year":"1996","journal-title":"effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.12.2270"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07952-7"},{"key":"e_1_2_10_11_2","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV\u20101 protease\u2010inhibitor\u2010associated lipodystrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr A","year":"1999","journal-title":"a cohort study"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/317491"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(01)00472-6"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00012"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012010-00004"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00201-4"},{"key":"e_1_2_10_17_2","first-page":"50","article-title":"Abnormalities of body fat distribution in HIV\u2010infected persons treated with antiretroviral drugs","volume":"31","author":"Bernasconi E","year":"2002","journal-title":"The Swiss HIV Cohort Study"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020794"},{"key":"e_1_2_10_19_2","first-page":"21","article-title":"Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance","volume":"44","author":"Puavilai G","year":"1999","journal-title":"1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization"},{"key":"e_1_2_10_20_2","unstructured":"World Health Organization. Diabetes Mellitus. Report of a WHO Study Group. Geneva WHO 1985 (Technical Report Series no. 727)."},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.43.4.535"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.7.1588"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.3.609"},{"key":"e_1_2_10_24_2","first-page":"253","article-title":"ISEC","volume":"50","author":"Hovorka R","year":"1996","journal-title":"a program to calculate insulin secretion"},{"key":"e_1_2_10_25_2","first-page":"916","article-title":"Attenuated GLP\u20101 secretion in obesity","volume":"38","author":"Ranganath LR","year":"1996","journal-title":"cause or consequence?"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1993.tb01995.x"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_10_28_2","first-page":"84","article-title":"Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy","volume":"2","author":"Thiebaut R","year":"2001","journal-title":"the Aquitaine Cohort, France, 1996\u201399"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00002"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200105040-00001"},{"key":"e_1_2_10_31_2","first-page":"F1","article-title":"Indinavir acutely inhibits insulin\u2010stimulated glucose disposal in humans","volume":"16","author":"Noor MA","year":"2002","journal-title":"a randomized, placebo-controlled study"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000228200"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.937"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.281.3.G752"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(98)00052-7"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200216030-00002"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509101597"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528509091657"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1982.242.5.E343"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-2-492"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1370127"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/me.15.9.1559"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.133.1.233"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00838486"},{"key":"e_1_2_10_46_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118411"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(99)00006-6"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00270.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00270.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:02:48Z","timestamp":1696950168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00270.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00270.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00270.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}